These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38904088)

  • 1. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.
    Khorramnia S; Navidi Z; Orandi A; Iravani MM; Orandi A; Malekabad ES; Moghadam SHP
    Clin Transplant Res; 2024 Jun; 38(2):136-144. PubMed ID: 38904088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
    Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
    Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the post hoc effectiveness of tixagevimab-cilgavimab for prevention of SARS-CoV-2 infections in solid organ transplant recipients.
    Jordan SC; Joung SY; Wang M; Tran TA; Bravo M; Masoom H; Chang C; Mendez M; Sun N; Patel J; Kittleson M; Frias E; Prostko JC; Ebinger JE; Cheng S; Sobhani K
    Transpl Infect Dis; 2024 Feb; 26(1):e14182. PubMed ID: 37885435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience.
    Cona A; Tavelli A; Agrenzano S; Hafeez N; Scianna G; Maria A; Marino F; Cruz E; Giorgio MD; Osorio E; Cucinella G; Luca A; Provenzani A; Vitulo P; Bertani A; Grossi PA; Mularoni A
    Microorganisms; 2024 Jul; 12(7):. PubMed ID: 39065204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.
    Sindu D; Razia D; Grief K; Cherrier L; Omar A; Walia R; Tokman S
    Transplant Direct; 2023 Jun; 9(6):e1485. PubMed ID: 37197016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
    Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
    Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
    Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
    Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients.
    Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M
    Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
    Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
    Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.
    Al-Obaidi MM; Gungor AB; Kurtin SE; Mathias AE; Tanriover B; Zangeneh TT
    Am J Med; 2023 Jan; 136(1):96-99. PubMed ID: 36181789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.
    Navidi Z; Pakzad Moghadam SH; Iravani MM; Orandi A; Orandi A; Ghazi SF; Fallah E; Malekabad ES; Khorramnia S
    Clin Transplant Res; 2024 Sep; 38(3):212-221. PubMed ID: 39344698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients.
    Benotmane I; Velay A; Gautier-Vargas G; Olagne J; Obrecht A; Cognard N; Heibel F; Braun-Parvez L; Keller N; Martzloff J; Perrin P; Pszczolinski R; Moulin B; Fafi-Kremer S; Thaunat O; Caillard S
    Am J Transplant; 2022 Nov; 22(11):2675-2681. PubMed ID: 35713984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges.
    Kapur R; Okumura K; Ohira S; Isath A; Gandhi A; Keller M; Nog R; Gass A; Spielvogel D; Lansman S; Dhand A
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38334977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
    Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
    Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response.
    Braitsch K; Jeske SD; Stroh J; Hefter M; Platen L; Bachmann Q; Renders L; Protzer U; Götze KS; Herhaus P; Verbeek M; Spinner CD; Bassermann F; Högner M; Haller B; Schneider J; Heider M
    Vaccines (Basel); 2024 Aug; 12(8):. PubMed ID: 39203997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients.
    Karaba AH; Kim JD; Chiang TP; Alejo JL; Sitaras I; Abedon AT; Eby Y; Johnston TS; Li M; Aytenfisu T; Hussey C; Jefferis A; Fortune N; Abedon R; Thomas L; Habtehyimer F; Ruff J; Warren DS; Avery RK; Clarke WA; Pekosz A; Massie AB; Tobian AAR; Segev DL; Werbel WA
    Am J Transplant; 2023 Mar; 23(3):423-428. PubMed ID: 36906295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tixagevimab-cilgavimab as pre-exposure prophylactic treatment against SARS-CoV-2 in kidney transplantation patients].
    Bravo González-Blas L; Menéndez García N; Fernández Prada M; Gago Fraile M; Suárez Fernández ML; Ridao Cano N
    Nefrologia (Engl Ed); 2024; 44(3):396-401. PubMed ID: 38331599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.